| Alogliptin: a novel molecule for improving glycemic control in type II diabetes mellitus. | |
| | |
MedLine Citation:
|
PMID: 20879969 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
Type 2 diabetes mellitus causes significant morbidity and mortality on account of its progressive nature and results in considerable burden on healthcare resources. It is characterized by high circulating levels of glucose resulting from insulin resistance and impaired insulin secretion. Current treatment strategies have only limited long-term efficacy and tolerability given the progressive nature of the disease leading to inadequate glycemic control and are also associated with undesirable side effects such as weight gain, hypoglycemia and gastrointestinal distress. In the light of these existing limitations, exploring new treatment targets and new therapies have become the need of the hour at present. The incretin pathway, in particular, glucagon-like peptide (GLP-1), plays an important pathological role in the development of type 2 diabetes mellitus, and treatments targeting the incretin system have recently generated surmount interest. These can mainly be categorized into two broad classes; GLP-1 agonists/analogs (exenatide, liraglutide), and dipeptidyl peptidase- 4 inhibitors (sitagliptin, vildagliptin). The gliptins act by prolonging the action of incretins, the gut hormones which can boost insulin levels. Alogliptin is a potent, highly selective dipeptidyl peptidase-4 inhibitor now undergoing clinical testing to support a new drug application for the treatment of type 2 diabetes. The results of Phase II and Phase III human studies, upon evaluation for clinical efficacy, safety and tolerability in patients with type 2 diabetes, have demonstrated that Alogliptin is effective and well tolerated as a treatment for type 2 diabetes, either as monotherapy or in combination with metformin, thiazolidinediones, sulfonylureas and insulin, with an excellent safety profile. |
| | |
Authors:
|
Somsuvra B Ghatak; Devang S Patel; Neeraj Shanker; Ambrish Srivstava; Shrikalp S Deshpande; Shital J Panchal |
Related Documents
:
|
20039889 - The effect of dpp-4 inhibition with sitagliptin on incretin secretion and on fasting an... 18239299 - Preparation of glucagon-like peptide-1 loaded plga microspheres: characterizations, rel... 19477229 - Effect of intracerebroventricular infusion of insulin on glucose-dependent insulinotrop... 19358859 - Effects of long-term dipeptidyl peptidase-iv inhibition on body composition and glucose... 1430079 - Temporal pattern of pancreatic insulin and c-peptide secretion and of plasma glucose le... 11473079 - Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable g... 20839379 - Helicobacter pylori cytotoxin-associated gene-a antibodies do not predict complications... 22027319 - Comparison of clinically relevant technical attributes of five insulin injection pens. 20410369 - Perception of the impact of type 1 diabetes on low-income families. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Current diabetes reviews Volume: 6 ISSN: 1875-6417 ISO Abbreviation: Curr Diabetes Rev Publication Date: 2010 Nov |
Date Detail:
|
Created Date: 2010-11-15 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101253260 Medline TA: Curr Diabetes Rev Country: United Arab Emirates |
Other Details:
|
Languages: eng Pagination: 410-21 Citation Subset: IM |
Affiliation:
|
Department of Pharmacology, Institute of Pharmacy, Nirma University, Sarkhej-Gandhinagar Highway, Ahmedabad 382 481, Gujarat, India. ghataksom16@gmail.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Continuous glucose monitoring in subjects with type 1 diabetes: improvement in accuracy by correctin...
Next Document: Nutritional overview on the management of type 2 diabetes and the prevention of its complications.